CN1279924C - Application of bioactive glass in preparing medicine for treating gastroduodenal ulcer - Google Patents
Application of bioactive glass in preparing medicine for treating gastroduodenal ulcer Download PDFInfo
- Publication number
- CN1279924C CN1279924C CN 200410095799 CN200410095799A CN1279924C CN 1279924 C CN1279924 C CN 1279924C CN 200410095799 CN200410095799 CN 200410095799 CN 200410095799 A CN200410095799 A CN 200410095799A CN 1279924 C CN1279924 C CN 1279924C
- Authority
- CN
- China
- Prior art keywords
- ulcer
- gastric
- bioactivity glass
- stomach
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to application of bioactive glass in manufacturing medicine for treating gastric ulcers and duodenal ulcers, which belongs to the field of biological medicine. The present invention is characterized in that bioactive glass is put into a soft capsule in the form of powder or liquid and enters a gaster or even an entire digestive system in the mode of swallow so as to achieve the purpose of treatment. The present invention has the treatment mechanism that on one hand, an acid environment is neutralized by the bioactive glass so as to prevent the deterioration of gastric ulcers and duodenal ulcers caused by gastric acid, and on the other hand, the bioactive glass has the function of promoting the growth of soft tissues to repair injuries of gastric mucosae so that cankers are prompted to heal.
Description
Technical field
The present invention relates to the application of a kind of bioactivity glass in the medicine of preparation treatment harmonization of the stomach duodenal ulcer.Belong to biomedicine field.
Background technology
The pathogenic factor of gastric duodenal ulcer disease and pathogenesis more complicated still do not have final conclusion so far.Since nearly 100 years, countries in the world are all constantly being studied and are being inquired into the pathogenic factor and the pathogeny of Peptic Ulcers, and existing tens of kinds of theories, but still the understanding of agreeing in the end.Main theory has following several:
(1) wound theory: the someone thinks that harmonization of the stomach duodenum primary injury is the reason of ulcer.The factor of these damages has the stimulation of mechanicalness, warm property, chemical.These stimulations make gastric mucosa injury; Become the starting point of " autopepsia ", develop into ulcer then.This theory has been set forth the exopathogenic factor that causes Peptic Ulcers, and obvious mistake is not pay attention to even more important endogenous cause of ill.Should, those wound factors only are exopathogenic factors, have only by certain endogenous cause of ill just can cause Peptic Ulcers.
(2) blood vessel theory: what have thinks coat of the stomach in blood supply just often, can not corroded by gastric juice.When the gastrointestinal blood vessel has pathological changes, make local gastric mucosa ischemic necrosis and cause ulcer.
(3) inflammation theory: find that according to the study 100% ulcer is seen the inflammatory lesion of stomach or duodenal mucosa simultaneously, and this pathological changes occurs in before the ulcer.Therefore think that gastritis is the ulcerated phase I, typical ulcer just can take place in that continues.
(4) digestion theory: the history in existing more than 100 year, it places increase and the increasing of pepsin amount of the increasing of gastric juice amount, gastric acidity above the other things.Thinking the increase of this gastric juice digestion power, is the pathogenetic Fundamentals of ulcer.So in the past primary disease was called " peptic ulcer ".But Peptic Ulcers patient is not to be that gastric acid increases, and the patient's gastric acid that has normally even also lacks.And ulcer might not take place in the very high people of some gastric acid.So the digestion theory has certain reason, but also can not illustrate with primary disease relevant various complicated problem takes place.
(5) the uneven theory of vegetative nerve: autonomic nervous dysfunction and Peptic Ulcers certain relation arranged.The basic shortcoming of this theory is that the influence of environmental condition is to external world underestimated, emphasizes to have broken away from the influence of higher nervous activity from the effect of autonomic nervous system to primary disease only isolatedly, and obviously be unilateral.
(6) cortex internal organs theory: often can see the case that makes Peptic Ulcers take place or increase the weight of because of spiritual emotional factor clinically.The founder Bei Kefu of cortex internal organs theory thinks that the disorder of cerebral cortex functional status is the leading factor of Peptic Ulcers generating process.The cerebral cortex moving obstacle makes the normal relation imbalance of cortex and subcortex, causes sympathetic nerve to be suppressed, and parasympathetic nervous tension force strengthens and formation ulcer.
(7) theory of infection: after the nineteen eighty-three people re-recognized helicobacter pylori (being called for short HP), the pathogeny of peptic ulcer had played an essence and has changed.Present most of expert thinks that HP is the main cause of peptic ulcer.As seen peptic ulcer should be considered to a kind of infectious disease, and after HP eradicated, peptic ulcer can obtain radical cure.
(8) other theories: except that above-mentioned several theories, organized acidosis theory, vitamin deficiency theory, neurotrophy theory, allergy theory, theory of heredity, endocrine theory or the like.These theories all have certain basis, but a lot of unilateral parts are also arranged.
Generally believe that now the pathogenic factor of Peptic Ulcers is not a kind of, but have due to the multiple factor effect.
Because relapse rate was very high after gastric ulcer was cured drug withdrawal, complication rate is higher, and natural history was 8～10 years, and maintenance drug therapy is an important measures.Medicine commonly used at present has: losec, cimetidine, ranitidine, famotidine, sucralfate, amoxicillin, SIDASHU etc.These medicines can only reach usually and improve sour environment raising pH in the stomach, suppress monoamine oxidase, MAO, improve the gastric mucosa blood circulation, suppress helicobacter pylori etc., but so far coat of the stomach gastric mucosa soft tissue injury is repaired directly, promotes that the medicine finding of the growth organized and healing is few.
Bioactivity glass has 30 years of researches history, and existing more than 15 year of successful clinical practice is the material of synthetic of the growth healing of at present unique growth, bone damaged healing can the promotion again soft tissue that can promote osseous tissue.These good characteristics of bioactivity glass derive from its surface activity.Current research shows, the surface activity of bioactivity glass can promote the generation of somatomedin, procreation, activating cell the gene expression [(1.D.Xynos of promotion cell, A.J.Edgar, L.D.K.Buttery, L.L.Hench, J.M.Polak, " Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution ", J.Biomed.Mater.Res., 55:151-157,2001).
(L.L.Hench, I.D.Xynos, A.J.Edgar, L.D.K.Buttery, J.M.Pohk, Zhong Jipin, Liu Xuanyong, Chang Jiang, " glass of activated gene, " Journal of Inorganic Materials, the 17th volume, the 5th phase, 897-909,2002)].Like this, bioactivity glass begins direct control with the gene of process by directly cell cycle being brought out in those adjustings, thereby strengthens and reached tissue is generated and the facilitation of growth.Current research shows simultaneously, bioactivity glass has stronger bactericidal action [P.Stoor in liquid environment, E.S derling and J.I.Saloen, " Antibacterial effectsof abioactive glass paste on oral microorganisms; " AGTA Odont01.Scand.56,161-165,1998.]
Application number is that 97191524 patent of invention " compositions of acceleration of wound and burn-healing and method " and application number are that 99802296 patent of invention " has used bioactive glass treatment of inflammation in skin conditions " and disclose bioactivity glass to form application technology to the healing of soft tissue wound.Bioactivity glass can promote the generation of soft tissue cells somatomedin, for the healing of wound provides the endogenous cell somatomedin.As detailed mechanism, we think that bioactivity glass reaches wound healing by the reaction of its surface activity.When bioactive glass particle when wound or soft group of injury region contact with the wound sepage, the accelerated surface reaction takes place, its result is: 1, ion discharges; 2, calcium, phosphorus plasma deposition generate a support shape hydroxyapatite layer on the bioactive glass particle surface: 3, to adsorb into fine microcell be other soft tissue growth cell and some protein growth factors to the high specific surface area of bioactive glass particle, these cells are subjected to the effect of the stable and somatomedin of hydroxyapatite shelf layer, this environment helps the generation of cell enlargement and new tissue, makes the bioactive glass particle surface become the bedding of a connective tissue and the growth of mucosa group; 4, bioactive glass particle surface reaction and ion discharge and improve wound or soft group of injury region pH[D.C.Greenspan, J.P.Zhong, G.P.LaTorre " The Evaluationof Surface Structure of BioactiVe Glasses In Vitro; " Bioceramics 7,1994.] suppress to infect, simultaneously, the ion of release can promote the generation of somatomedin, the growth that promotes the mucosal tissue cell, the gene expression of activating cell.All these effects have reached the effect that promotes wound and mucosal tissue wound healing.
Bioactivity glass uses in the clinical practice of treatment epidermis soft tissue wound healing.Clinical showing, bioactivity glass comprises that in the healing that promotes the wound surface ulcer healing particularly to be difficult to heal wound surface diabetic ulcer, decubital ulcer, long-term rotten to the corn wound, oral ulcer, fat liquor voltinism wound, minor burn etc. have presented good result [Cai Rui, Liao Zhenjiang, model jump group, Zhang Shenghua etc., " skin is given birth to clinical efficacy investigation report one skin and given birth to DermGlas clinical practice data " Huashan Hospital Attached to Medical Collage of Fudan Univ., attached Yueyang hospital of Shanghai Univ. of Traditional Chinese Medicine, the attached sweet spring water of Tongji University's medical college hospital, in August, 2000).
Thereby this shows according to bioactive glass particle surface reaction and ion and discharge the raising soft tissue injury pH of place, promote the growth of mucosal tissue cell to reach the principle of soft tissue injury healing that bioactivity glass should be very good to the treatment of gastric ulcer, duodenal ulcer and digestive system and ulcer.Regrettably the bioactivity glass treatment that is used for gastric ulcer and duodenal ulcer does not appear in the newspapers so far as yet.
Goal of the invention
The object of the invention is to provide the application of a kind of bioactivity glass in the medicine of preparation treatment harmonization of the stomach duodenal ulcer.Its mechanism of action be " bioactivity glass in the body fluid environment, surface reaction takes place, surrounding pH is increased, thus in and sour environment stop the deterioration of the gastric duodenal ulcer that causes because of gastric acid.More particularly, the result that bioactive glass surface reaction and ion discharge can promote the growth of soft tissue cells, and the healing that reaches the mucosa tissue damage is a ulcer healing.This two specific character all is crucial to the treatment of gastric duodenal ulcer.Yet there are no the medicine of the treatment gastric duodenal ulcer that has this two specific character simultaneously.Particularly can promote the growth of soft tissue cells, directly reach mucosa tissue damage is that the medicine of ulcer healing is not seen clinically yet and used.Therefore, bioactivity glass will be the specific medicine to the treatment gastric duodenal ulcer.
The bioactivity glass compositing formula of using in the medicine of preparation treatment gastric duodenal ulcer provided by the invention is: (weight)
SiO
2 40-60％
CaO 10-30％
Na
2O 10-35％
P
2O
5 2-8％
B
2O
3 0-10％
K
2O 0-8％
MgO 0-5％
Described bioactivity glass is packed into powder or liquid form in the soft capsule, and mode enters stomach and even full digestive system arrives therapeutic effect to swallow.
The granule of described bioactivity glass powder is less than 20 microns.
Bioactivity glass provided by the invention can be treated harmonization of the stomach duodenum and digestive system and ulcer, stop the deterioration of the gastric duodenal ulcer that causes because of gastric acid in its energy with sour environment, what promote soft prevention growth is used for repairing gastric mucosa, promotes ulcer healing.
Use in the medicine of preparation gastric duodenal ulcer in order to verify bioactivity glass; after the inventor makes medicine doubly your rubber capsule by name with described bioactivity glass powder (less than 20 μ m), carried out respectively to mice acute toxicity test, to the protective effect of mice stress gastric ulcer and to three animal experiments of the therapeutical effect of the drug-induced gastric ulcer of rat.(seeing embodiment 3,4,5 for details)
Three animal experiments all entrust The 2nd Army Medical College pharmacology teaching and research room in Shanghai to carry out, and be 2003.12.7-2004.4.14 date of test.Raw data is kept at associate professor Liu Jianguo of this teaching and research room place.Conclusion (of pressure testing) is respectively:
(1) mouse stomach doubly you to give birth to a capsular maximum tolerated dose (MTD) be 20g/kg, male female 2 groups of mortality rates all are lower than 50%, obey 6 as the people at every turn, every 0.5g, then this maximum tolerated dose is equivalent to 400 times of clinical people's consumption.
(2) with 10% doubly you give birth to 0.5g/kg and irritate the stress ulcer that stomach brings out mice the better protect effect is arranged.
(3) give birth to 0.5g/kg filling stomach with 10% doubly that the SD rat gastric ulcer that reserpine brings out is had therapeutical effect preferably.
This shows that bioactivity glass provided by the invention has a good application prospect in the medicine that preparation treatment harmonization of the stomach 12 refers to burst.
Description of drawings
The PH of accompanying drawing 1 simulation human body solution is with the variation in bioactive glass surface response time.
Accompanying drawing 2 bioactivity glass are to the healing of soft tissue injury
1. before the medication
2. two weeks of medication, wound healing 75%
3. full healing around the medication
The specific embodiment
Below by specific embodiment, the effect of bioactivity glass in ulcer treatment is described, with further elaboration substantive distinguishing features of the present invention and marked improvement.
The variation of embodiment 1, bioactivity glass pH in anthropomorphic dummy's liquid solution
The bioactive glass powder of 0.2 gram＜20 μ m is put into 200ml anthropomorphic dummy liquid solution react under human body temperature (37 ℃), the initial pH of anthropomorphic dummy's liquid solution is 7.25.In course of reaction, the pH that notes anthropomorphic dummy's liquid solution over time.Figure one is the experimental record result, and on behalf of the pH in the compositing range, the error amount among the figure change.Figure one shows that the pH of anthropomorphic dummy's liquid solution raises with the bioactive glass surface reaction.This characteristic makes that bioactivity glass neutralizes in gastric acid environment acid, stops the deterioration of the gastric duodenal ulcer that causes because of gastric acid.
The anthropomorphic dummy's liquid solution that uses in the present embodiment is referred to as the Tris buffer.The Tris Full Name in English is Tris (Hydroxymethyl) aminomethane, and molecular formula is C4H1, N03, Chinese three (methylol) aminomethane by name.It is people's liquid solution that the Tris buffer is used as the simplest simulation biotic environment in the world.
Tris buffer formulation compound method is:
Deionized water: 700ml
Tris： 6.069g
HCl(1N)： 35ml
In the beaker of 1500ml, prepare, keep stirring.Mix the back to going in the 1000ml hopper, adding deionized water at last, to make solution be 1000ml.Mixing and stirring then.PH is about 7.25.
Embodiment 2, bioactivity glass are to the healing of soft tissue injury
The patient does left mastocarcinoma radical correction on May 4th, 2000, two week backs find that there is the ulcer wound surface of 5 * 6 * 0.7cm sides, every day the routine poor effect of changing dressings.Begin external bioactivity glass (skin is given birth to) powder after 3 weeks and change dressings, healing speed is obviously accelerated.After 1 week of medication, minimizing is oozed out in the granulation growth, wound healing 50%, and medication 2 all wound healings 75%, 4 weeks of medication are healed (see figure 2) fully.
Bioactivity glass can promote soft tissue cells as becoming the generation of fine microcell somatomedin, for the healing of wound provides the endogenous cell somatomedin, thereby the soft tissue wound is reached as testing reparation shown in three and healing.Mucosa tissue is a kind of soft tissue, and bioactivity glass applicable to mucosa tissue, reaches reparation and treatment to the damage of gastric duodenal ulcer mucosa tissue to the repair mechanisms of exocuticle soft tissue injury.
Embodiment 3, times your a rubber capsule are irritated the acute toxicity test of stomach to mice
(1) tried thing
Title: times that rubber capsule
Character: white powder
Lot number: 030930
The unit of providing: doctor Zhong Jipin
Solvent: normal saline
Compound method: face with before being mixed with 50% concentration.
(2) animal subject
The source: Kunming mouse provides (cleaning level) by the department of the Chinese Academy of Sciences of Fudan University in Shanghai laboratory animal section.
The quality certification number: SCKX (Shanghai) 20002-0002.
Body weight: 18-22g
Sex: male and female half and half
Grouping: male group 13, female group 13.
(3) dosage
Every group of dosage is respectively 20g/kg
(4) administration volume 0.4ml/ (10g body weight)
(5) route of administration is irritated stomach
(6) administration number of times once/day
(7) the method healthy mice is totally 26, fasting 12 hours (water supply), and 13 every group, male and female half and half, by maximum molten long-pending (0.4ml/kg) and Cmax gastric infusion, the dosage of administration group mice is 20g/kg (its corresponding administration concentration is 0.5g/ml).
(8) observation index
Toxic reaction: observe animal toxicity response situation and death condition, comprise poisoning symptom, poisoning time of origin, persistent period, convalescent period and death time of animal etc.
Observation period: 7 days
(9) animal is dispirited few moving after the administration as a result, in 24 hours male group dead 2 (mortality rate 15.39%), female group dead 4 (mortality rate 30.77%), dead mice 1 has only hematuria, 1 eye has a large amount of secretions, other dysoemias, anatomical organs is no abnormal, and other mices recover after 24 hours gradually.Observe continuously and do not occur any animal dead in `7 days again.
(10) conclusion doubly your a rubber capsule maximum tolerated dose (MTD) of irritating the stomach mice be 20g/kg, male female 2 groups of mortality rates all are lower than 50%, obey 6 as the people at every turn, every 0.5g, then this maximum tolerated dose is equivalent to 400 times of clinical people's consumption.
Embodiment 4, the doubly living protective effect of that to the mice stress gastric ulcer
This experimentation is to observe doubly, and you give birth to the protective effect to the mice stress ulcer.Experiment divides 2 groups, be negative control group and medication therapy groups, give respectively and normal saline and 10% doubly you give birth to solution and irritated 3 days, irritate for the last time behind the stomach and mice to be lain on the back fixing in 30 minutes, with 22～23 ℃ of cold water soak, horizontal plane reaches mice xiphoid-process position, soaks and puts to death mice after 7 hours, takes out stomach, the silk thread ligation of pylorus place, inject 10% formalin from esophagus and make gastric filling, fix 30 minutes tailing edge greater gastric curvatures and cut stomach open, a situation arises to observe 2 groups of gastric ulcers.
Experiment shows: doubly you give birth to the filling stomach has the better protect effect to the mice stress ulcer
This test is concrete to divide following 10 parts to describe:
(1) experiment purpose
Doubly you give birth to the protective effect of filling stomach to the mice stress gastric ulcer by this laboratory observation.
(2) be subjected to the reagent thing
Doubly you give birth to: product batch number is provided by doctor Zhong Jipin: 20030930, and concentration: be configured to 10% suspension with normal saline, outward appearance is creamy white.
(3) animal subject
Healthy Kunming mouse (providing) 24 by the The 2nd Army Medical College Experimental Animal Center, body weight 20 ± 2g, male female dual-purpose is divided into 2 groups at random
| Grouping | Number of animals (only) | Dosage | Route of administration |
| Normal saline group treatment group | 12 12 | Doubly you give birth to 0.5g/kg to normal saline 5ml/kg | Irritate stomach and irritate stomach |
(4) experimental technique
The treatment group is given birth to 10% times of that and is irritated stomach, matched group is irritated stomach with normal saline, once a day, for three days on end, fasting was 24 hours in the 4th day, with treatment group and matched group respectively with 10% doubly you give birth to liquid and normal saline and irritate behind the stomach mice to be lain on the back in 30 minutes and be fixed on the plank, put into 22～23 ℃ of cold water, horizontal plane is flowed or blow over and cover completely to the xiphoid-process place and was soaked 7 hours, put to death animal then, take out stomach, pylorus ligation, inject 10% formalin solution to stomach from esophagus and be full shape, cut inspection ulcer situation open and do grading mensuration from greater gastric curvature after 30 minutes.
(5) observation index:
Ulcer index: O level: no pathological changes; 1 grade: hemorrhage, rotten to the corn or take place the ulcer point (＜1mm); 2 grades: 1～5 aphtha (＞1mm,＜3mm); 3 grades: 6 above aphthas or 1 big ulcer (＞3mm); 4 grades: big ulcer more than 2; 5 grades: perforated ulcer.
(6) dosage setting
Treatment group 500mg/kg (is equivalent to people's 10 multiple doses; The people obeys 6 capsules by 60 kilograms at every turn, and every capsules calculates then by 0.5g that the clinical consumption of people is 50mg/kg)
(7) medication
The medication that experiment is adopted is a gastric infusion, and is oral consistent with approach with clinical plan.The administration volume is 5ml/kg, and administration number of times is for once.
(8) statistical analysis
Experimental result is represented with X ± S, adopts non-paired t test method statistics, and P＜0.05 is for having notable statistics difference.
(9) experimental result
Through with 10% times you give birth to 500mg/kg and normal saline 5ml/kg irritates stomach once a day, for three days on end, irritate for the last time behind the stomach mice to be immersed in 22～23 ℃ of cold water in 30 minutes and found normal saline group ulcer incidence rate 100%, ulcer index 2.92 ± 1.17 in 7 hours.And treatment group ulcer incidence rate is 83.33%, and ulcer index is that relatively there were significant differences between 1.75 ± 1.14, two groups, and see the following form (P＜0.05).
Doubly you give birth to the protective effect n=12 to the SD rat gastric ulcer
| Group | Ulcer incidence rate % | Ulcer index |
| The normal saline group | 100 | 2.92±1.17 |
| The treatment group | 83.33 | 1.75±1.14* |
*P＜0.05
(10) experiment conclusion
The stress ulcer that doubly your living 0.5g/kg filling stomach with 10% brings out mice has the better protect effect.
Embodiment 5, times that are given birth to the therapeutical effect to the drug-induced gastric ulcer of rat
This experimentation is observed doubly, and you give birth to the therapeutical effect that reserpine is brought out the SD rat gastric ulcer.Experiment divides 2 groups, i.e. negative control group and medication therapy groups, and after model prepared, negative control group was irritated stomach with normal saline, and the treatment group is irritated stomaches all once a day, continuous 7 days for 2 groups with doubly you give birth to solution and irritate stomach.
Experiment shows: doubly you give birth to the filling stomach has preferably and therapeutical effect the SD rat gastric ulcer that reserpine brings out
Specifically can divide following 10 parts, be described in detail
(1) experiment purpose
By this laboratory observation times that is living reserpine is brought out SD rat gastric ulcer therapeutical effect.
(2) be subjected to the reagent thing
Doubly you give birth to: product batch number is provided by doctor Zhong Jipin: 20030930, and concentration: be configured to 10% suspension with normal saline, outward appearance is creamy white.
The reserpine injection: red flag pharmaceutical factory of Shanghai Medical Univ produces, and authentication code: the accurate word (1995) of medicine is defended No. 043022 in Shanghai, and 1mg/ props up.
(3) animal subject
20 of healthy SD rats (providing) by the The 2nd Army Medical College Experimental Animal Center, the quality certification number: SCXK (Shanghai) 2003-0002, body weight 318 ± 87g, male female dual-purpose is divided into 2 groups at random
| Grouping | Number of animals (only) | Dosage | Route of administration |
| Normal saline group treatment group | 10 10 | Doubly you give birth to 0.5g/kg to normal saline 5ml/kg | Irritate stomach and irritate stomach |
(4) experimental technique
Animal subject fasting 24 hours is freely drunk water, then lumbar injection reserpine 5mg/kg, can form ulcer after 24 hours, normally raise, the treatment group is given birth to solution 0.5g/kg filling stomach once with 10% doubly that every day, the matched group normal saline is irritated stomach once a day, and capacity is identical with the treatment group.Put to death animal after 7 days, take out stomach,, inject 10% formalin solution to stomach from esophagus and be full shape, cut open from greater gastric curvature after fixing 30 minutes and check the ulcer situation and do grading and measure pylorus ligation
(5) observation index:
Ulcer index: O level: no pathological changes; 1 grade: hemorrhage, rotten to the corn or take place the ulcer point (＜1mm); 2 grades: 1～5 aphtha (＞1mm,＜3mm); 3 grades: 6 above aphthas or 1 big ulcer (＞3mm); 4 grades: big ulcer more than 2; 5 grades: perforated ulcer.
(6) dosage setting
Treatment group 500mg/kg (is equivalent to people's 10 multiple doses; The people obeys 6 capsules by 60 kilograms at every turn, and every capsules calculates then by 0.5g that the clinical consumption of people is 50mg/kg)
(7) medication
The medication that experiment is adopted is a gastric infusion, and is oral consistent with approach with clinical plan.The administration volume is 5ml/kg, and administration number of times is for once.
(8) statistical analysis
Experimental result is represented with X ± S, adopts non-paired t test method statistics, and P＜0.05 is for having notable statistics difference.
(9) experimental result
Bringing out the SD rat with the reserpine lumbar injection takes place after the ulcer respectively with normal saline and doubly you give birth to after a filling stomach treats a week normal saline group ulcer incidence rate 100%, ulcer index 3.10 ± 0.57.And treatment group ulcer incidence rate is 70%, and ulcer index is that relatively there were significant differences between 1.80 ± 1.62, two groups, and see the following form (P＜0.05).
Doubly you give birth to the protective effect n=10 to the SD rat gastric ulcer
| Group | Ulcer incidence rate % | Ulcer index |
| The normal saline group | 100 | 3.10±0.57 |
| The treatment group | 70 | 1.80±1.62* |
*P＜0.05
(10) experiment conclusion
Doubly you living 0.5g/kg with 10% irritates stomach has therapeutical effect preferably to the SD rat gastric ulcer that reserpine brings out.
Claims (5)
1, a kind of bioactivity glass is characterized in that the weight that consists of of (1) described bioactivity glass as the application of preparation treatment to the gastric duodenal ulcer medicine:
SiO2 40-60％
CaO 10-30％
Na
2O 10-35％
P
2O
5 2-8％
B
2O
3 0-10％
K
2O 0-8％
MgO 0-5％
(2) bioactivity glass is packed in the soft capsule with the form of powder or liquid, enters stomach and even whole digestive system in the mode of swallowing.
2, by the application of the described bioactivity glass of claim 1 as preparation treatment gastric duodenal ulcer medicine, the powder granule of the soft capsule that it is characterized in that packing into is less than 20 microns.
3,, it is characterized in that protective effect being arranged with the stress ulcer that 10% bioactivity glass 0.5g/kg filling stomach brings out mice by the application of claim 1 or 2 described bioactivity glass as preparation treatment gastric duodenal ulcer medicine.
4, press claim 1 or 2 described bioactivity glass as the application of preparation treatment, it is characterized in that the bioactivity glass 0.5g/kg filling stomach with 10% has therapeutical effect to the SD rat gastric ulcer that reserpine brings out the gastric duodenal ulcer medicine.
5, press claim 1 or 2 described bioactivity glass as the application of preparation treatment to the gastric duodenal ulcer medicine, your maximum tolerated dose of rubber capsule mouse stomach is 20g/kg to it is characterized in that making doubly by described bio-vitric.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410095799 CN1279924C (en) | 2003-11-14 | 2004-11-12 | Application of bioactive glass in preparing medicine for treating gastroduodenal ulcer |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200310108632 | 2003-11-14 | ||
| CN200310108632.1 | 2003-11-14 | ||
| CN 200410095799 CN1279924C (en) | 2003-11-14 | 2004-11-12 | Application of bioactive glass in preparing medicine for treating gastroduodenal ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1636576A CN1636576A (en) | 2005-07-13 |
| CN1279924C true CN1279924C (en) | 2006-10-18 |
Family
ID=34862466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410095799 Expired - Fee Related CN1279924C (en) | 2003-11-14 | 2004-11-12 | Application of bioactive glass in preparing medicine for treating gastroduodenal ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1279924C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013538858A (en) | 2010-10-02 | 2013-10-17 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | Minimizing bowel dysfunction |
| CN103006700B (en) * | 2011-09-20 | 2016-08-17 | 常州倍尔生生物科技有限公司 | PH buffer activity glass and its production and use |
| CN106798751A (en) * | 2016-12-14 | 2017-06-06 | 石家庄诺利达医疗器械有限公司 | Functional bioactive glass and its production and use |
| CN106619714A (en) * | 2016-12-14 | 2017-05-10 | 石家庄诺利达医疗器械有限公司 | Functional bioactive glass as well as preparation method, application method and application thereof |
-
2004
- 2004-11-12 CN CN 200410095799 patent/CN1279924C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1636576A (en) | 2005-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0664133B1 (en) | Preparation "ostim apatite" for stimulating growth in bone tissue | |
| CN1026064C (en) | Preparation process for composite inhibiting activated | |
| JP2021527121A (en) | Silk-based product formulation and usage | |
| CN106999635A (en) | Repair of cartilage graft support and its manufacture method | |
| CN1907358A (en) | Pharmaceutical composition for preventing and treating avian coccidiosis and its preparing method | |
| CN1101260A (en) | Material for adjusting function of biology | |
| CN108721320A (en) | The application of micromolecule hyaluronic acid segment | |
| JP6765540B2 (en) | Dermis layer for transplantation with increased engraftment rate and its manufacturing method | |
| CN101053568A (en) | Compound and its processing technology for compound sulfamonomethoxine sodium injection | |
| CN1279924C (en) | Application of bioactive glass in preparing medicine for treating gastroduodenal ulcer | |
| CN1196480C (en) | Application of calcium L-threonate for curing fracture | |
| WO2005067948A2 (en) | Biological medicine for treating various diseases caused by various virus, bacterial infection | |
| CN1917891A (en) | Medicament on the basis of honey, preparation and use thereof | |
| CN109464651A (en) | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine | |
| CN1895275A (en) | Calf-blood deprotein extract gel | |
| CN101053657A (en) | External applied preparations for treating intractable skin ulcer | |
| CN1132585C (en) | Water soluble medical chitose preparation and its preparation | |
| CN1868483A (en) | Injection for treating eperythrozoonosis of domestic animal and its prepn. method | |
| CN1193779C (en) | Vagina cleaning and antiphlogistic suppository and its preparing method | |
| CN1344540A (en) | Application of calcium L-threonate in treating cartilage related diseases | |
| CN1751690A (en) | Compound injection contg. alendronate sodium and vitamin D3 | |
| Ray et al. | Osteoporosis and Its Nanotechnology-Based Advanced Treatment—An Overview | |
| RU2010141597A (en) | METHOD FOR TREATING ONCOLOGICAL DISEASES | |
| CN114099419B (en) | Sodium hydrosulfide-loaded injectable nano-fibrosis hydrogel and preparation method and application thereof | |
| CN111773180B (en) | Application of mannan in inducing bone regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061018 Termination date: 20161112 |